Causal Relationship and Shared Genetic Loci between Psoriasis and Type 2 Diabetes through Trans-Disease Meta-Analysis
- PMID: 33385400
- PMCID: PMC8154633
- DOI: 10.1016/j.jid.2020.11.025
Causal Relationship and Shared Genetic Loci between Psoriasis and Type 2 Diabetes through Trans-Disease Meta-Analysis
Abstract
Psoriasis and type 2 diabetes (T2D) are complex conditions with significant impacts on health. Patients with psoriasis have a higher risk of T2D (∼1.5 OR) and vice versa, controlling for body mass index; yet, there has been a limited study comparing their genetic architecture. We hypothesized that there are shared genetic components between psoriasis and T2D. Trans-disease meta-analysis was applied to 8,016,731 well-imputed genetic markers from large-scale meta-analyses of psoriasis (11,024 cases and 16,336 controls) and T2D (74,124 cases and 824,006 controls), adjusted for body mass index. We confirmed our findings in a hospital-based study (42,112 patients) and tested for causal relationships with multivariable Mendelian randomization. Mendelian randomization identified a causal relationship between psoriasis and T2D (P = 1.6 × 10‒4, OR = 1.01) and highlighted the impact of body mass index. Trans-disease meta-analysis further revealed four genome-wide significant loci (P < 5 × 10‒8) with evidence of colocalization and shared directions of effect between psoriasis and T2D not present in body mass index. The proteins coded by genes in these loci (ACTR2, ERLIN1, TRMT112, and BECN1) are connected through NF-κB signaling. Our results provide insight into the immunological components that connect immune-mediated skin conditions and metabolic diseases, independent of confounding factors.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest
JEG received research grants from AbbVie, AnaptysBio, Pfizer, Novartis, Celgene, and Eli Lilly, and serves as advisory board in Novartis, AbbVie, Eli Lilly, MiRagen, and Almirall. NNM is a full-time US government employee and has served as a consultant for Amgen, Eli Lilly, and Leo Pharma receiving grants/other payments; as a principal investigator and/or investigator for AbbVie, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding; and as a principal investigator for the National Institute of Health receiving grants and/or research funding.
Figures
References
-
- Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. Journal of the European Academy of Dermatology and Venereology : JEADV 2013;27(11):1329–35. - PubMed
-
- Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Molecular and cellular biochemistry 2011;351(1–2):197–205. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R56 DK062370/DK/NIDDK NIH HHS/United States
- K08 AR060802/AR/NIAMS NIH HHS/United States
- R01 AR042742/AR/NIAMS NIH HHS/United States
- R01 AI130025/AI/NIAID NIH HHS/United States
- R01 DK062370/DK/NIDDK NIH HHS/United States
- U01 DK062370/DK/NIDDK NIH HHS/United States
- P30 AR075043/AR/NIAMS NIH HHS/United States
- K01 AR072129/AR/NIAMS NIH HHS/United States
- R01 AR054966/AR/NIAMS NIH HHS/United States
- R01 AR050511/AR/NIAMS NIH HHS/United States
- R01 AR065183/AR/NIAMS NIH HHS/United States
- R01 AR063611/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
